Wooly Mammoth startup Colossal seeking at least $20B valuation
De-extinction startup Colossal Biosciences is reportedly seeking a valuation between $20 billion and $30 billion in a new funding round.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Colossal Biosciences, a startup focused on de-extinction and the wooly mammoth, is in talks to raise new capital. The company is seeking a valuation starting at $20 billion, with some reports indicating it could reach $30 billion.
Coverage from TechCrunch, Axios, Seeking Alpha, Zamin.uz, and Межа. Новини України emphasizes that these figures are currently being discussed or reported as part of a new funding round. Future developments depend on the outcome of these capital raising talks and whether the company secures the targeted valuation.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Quick answers
What is the target valuation for Colossal Biosciences?
The company is seeking at least $20 billion, with some reports suggesting a range up to $30 billion.
What is Colossal Biosciences' primary focus?
It is described as a de-extinction startup focused on the wooly mammoth.
What is the purpose of the current talks?
The company is reportedly in discussions to raise new capital.
Coverage (5)
- Colossal Biosciences seeks 20 to 30 billion valuation in new funding round Межа. Новини України. · 1d ago
- Colossal Biosciences, the de-extinction startup, could reach a $30 billion valuation Zamin.uz · 1d ago
- Colossal Biosciences discussing new funding at $20B or more valuation: report (IBB:NASDAQ) Seeking Alpha · 1d ago
- Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation TechCrunch · 1d ago
- Wooly Mammoth startup Colossal seeking at least $20B valuation Axios · 1d ago
Topics
Related trends
Plants that make real dairy protein? Scientists discover an unexpected shortcut
Scientists have unlocked a biotechnological shortcut allowing plants to produce bovine casein, a key dairy protein, without the need for cows.
Which ‘AI scientist’ suits your lab? A guide for the perplexed
Anthropic has launched a dedicated research workbench for oncology and drug discovery, prompting broad analysis of AI integration in scientific laboratories.
The data that led an AI biotech to pick up Novo's Parkinson's stem cell therapy
An AI biotech firm has acquired Novo's Parkinson's stem cell therapy following promising results from the first human trials.
'We're paranoid.' As China biotech competition heats up, American drugmakers get more secretive
6 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
'Mitch' protein that could change the future of weight loss and fat burning
Researchers have identified a protein called 'Mitch' that regulates fat storage and energy usage in cells.
AI Training Startup Mercor Discusses $20 Billion Valuation
AI data labeling startup Mercor is in discussions to secure a $20 billion valuation following reports of substantial revenue growth.